Kalypsys, Inc. On Track To Complete Phase Ia Study for Drug Candidate, KD3010, For Metabolic Disorders By End Of October
SAN DIEGO--(BUSINESS WIRE)--Kalypsys Inc. announced today that it has initiated and expects to complete a Phase Ia clinical trial of KD3010, a small molecule Peroxisome Proliferator-Activator Receptor Delta (PPAR Delta) agonist for the treatment of metabolic disorders, including obesity, by the end of October.